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ABSTRACT: Metastatic cancer to the pancreas accounts for less than 2% of all pancreatic 
malignancies, with renal cell carcinoma being the predominant type. We report the case of 
an elderly patient detected with a solitary lesion in the head of the pancreas, 6 years after a 
nephrectomy for renal cell carcinoma. The patient underwent a pancreaticoduodenectomy 
for the same. A review of literature showed isolated pancreatic metastasis to be rare, 
ranging from 0.5 to 3%. Patients are usually asymptomatic, unless the tumor enlarges. 
Spread usually takes place by the hematogenous route or via lymphatics, direct spread 
being very unusual. Surgical resection seems to be the standard of care for isolated 
metastasis from renal cell carcinoma as the other modalities of treatment seem 
unresponsive. Typically, patients undergo a pancreaticoduodenectomy or distal 
pancreatectomy depending on the location of the tumor. Atypical resections are done in 
certain situations. Surgery is carried out in favourable candidates and a thorough 
evaluation needs to be done intraoperatively for multiple metastases. Histology revealed a 
metastatic renal cell carcinoma confirmed on immunohistochemistry. All margins were 
free of tumor without lymphnodal involvement. Eight months after the surgery the patient 
is doing well. As compared to primary pancreatic cancer, metastasis from renal cell 
carcinoma has a higher resectability rate. Solitary metastasis to the pancreas has a good 
prognosis especially in renal cell carcinoma, with a 5 years survival rate of 43 to 88%. 
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INTRODUCTION
ᴪ 
 
Metastasis to the pancreas is usually associated 
with extensive disease and a dismal prognosis. 
Resection is recommended only in cases of isolated 
metastasis. Eighty percent of resections reported 
for metastasis to the pancreas result from four 
primary cancer types: renal cell carcinoma, 
colorectal carcinoma, sarcoma and melanoma
1,2.
 
Pancreatic metastasis from renal cell carcinoma 
presents synchronously with wide spread metastatic 
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disease in 12% of cases and therefore surgical 
resection may not be favorable
2,3. However, the 
overall 5 year survival for a solitary metastasis in 
the pancreas treated with resection ranges between 
43 and 88 %
1-4 . 
 
CASE REPORT 
 
A 70 year old gentleman underwent a right radical 
nephrectomy for renal cell carcinoma 6 years ago. 
The 9×8 cm tumor was present in the upper pole of 
the right kidney. The tumor was classified as grade 
II in the Furham’s nuclear grading system. There 
was no capsular or vascular involvement and the 
ureter and hilar lymph nodes were free of tumor. 
However, the tumor also involved the calyx. 
Contrast enhanced computed tomography (CECT) 
of abdomen revealed no metastasis and patient was Bhalla et al / Solitary pancreatic metastasis from renal cell carcinoma 
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staged as T3aN0M0.  Post operatively the patient 
has been on regular follow-up with 6 monthly 
blood investigations, CECT abdomen and X-ray 
chest. 
Eight months back he reported with vague 
abdominal pain with loss of weight and appetite. 
Ultrasonography of abdomen showed a lesion in 
the head of the pancreas. Biochemical 
investigations were within normal limits. 
Preoperative carbohydrate antigen (CA) 19-9 level 
was normal. Endoscopic ultrasonography (EUS) 
revealed a mass in the head of pancreas and fine 
needle aspiration (FNA) showed a clear cell tumor 
suggestive of renal cell carcinoma. CECT abdomen 
(Figure 1) revealed a mass in the head of pancreas 
of size 3x3 cm without any common bile duct 
dilatation. A classical pancreaticoduodenectomy 
was performed. Intraoperatively, there was a 3x3 
cm lesion in the pancreatic head without any 
regional lymphadenopathy. Postoperative course 
was uneventful and the patient was discharged after 
7 days. 
Histology revealed metastatic clear cell carcinoma, 
arranged in varying-sized alveolar aggregates 
(Figure 2). The tumour cells showed clear 
cytoplasm and mild to moderate nuclear 
pleomorphism, (Furhman’s nuclear grading I/II.) 
Immunohistochemistry studies confirmed a 
metastatic renal cell carcinoma (cytokeratin, 
Epithelial Membrane Antigen (EMA), vimentin 
and Clustered Designate (CD) 10 positive) with a 
proliferative index of 4%. 
A final diagnosis of metastatic clear cell renal cell 
carcinoma in the head of the pancreas was reached. 
The surgical margins were free of tumor. No lymph 
nodal (LN) metastasis was detected. Patient has 
remained well till his last follow-up. 
 
 
Figure 1: CECT image of an isolated, brightly 
enhancing mass in the head of pancreas 
 
 
Figure 2:  Microscopic picture showing alveolar aggregates of clear cells. Alongside showing clear cell 
tumour in the head of pancreas 
 
DISCUSSION 
 
The pancreas is a rare site of solitary metastasis but 
it is often involved in diffuse metastatic disease. 
For all sites included, synchronous metastases from 
RCC occur in 25-30% and metachronous 
metastases in about 40% of patients
5. The incidence 
of metastases from primary renal cell carcinoma to 
pancreas ranges from 0.5 to 3%
2-4, lung being the 
most common
5. Metastasis often presents many 
years after a nephrectomy
2- 5. 
A case of this nature has been previously reported 
from India on one occasion
6. In a review of 
literature in 236 cases of isolated pancreatic 
metastasis of RCC, Sellner et al
3 reported 35% of 
these patients to be asymptomatic with others 
presenting with symptoms of abdominal pain 
(20%), GI bleeding (20%), obstructive jaundice 
(9%), weight loss (9%) and pancreatitis and 
diabetes (3%) each. The patients are usually 
asymptomatic. Usually, the symptoms arise when 
the tumor increases in size. The median tumor 
diameter in the asymptomatic subgroup was 
reported to be 25mm (range: 14 - 48mm) as 
compared to 45mm in symptomatic group
4. Bhalla et al / Solitary pancreatic metastasis from renal cell carcinoma 
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The mode of spread can either be hematogenous or 
via lymphatics with direct spread to the pancreas 
being unusual. Spread through lymphatics may 
occur by retrograde lymph flow secondary to tumor 
infiltration of the retroperitoneal lymph nodes. 
Haematogenous spread may occur along the 
collateral vein of a hyper vascular renal tumor with 
or without associated renal vein thrombosis
7. 
Sellner et al
3, reported that pancreatic metastasis 
occurred in all parts of pancreas irrespective of 
whether the renal cell carcinoma was from the right 
or the left kidney. They were not able to find 
normal and abnormal lymphatics and venous 
communication between renal cell carcinoma and 
pancreas
3. They also failed to find a relationship 
between the site of isolated pancreatic metastasis 
and the site of primary renal cell carcinoma
3. This 
favours hematogenous systemic spread but is not 
able to explain a preference for pancreatic 
metastasis as compared to other organ metastasis. 
One explanation is that the tumor cell biology that 
had a high affinity for the parenchyma of the 
pancreas and supported by the finding of late 
metachronous metastasis in the residual pancreas
3. 
Surgical resection of primary renal cell carcinoma 
and metastatic deposits remains the most effective 
treatment since the chemotherapy, radiotherapy and 
hormonal therapy have proven ineffective
2,8. A 
solitary resectable metastasis of an RCC or 
multiple metastases confined to one organ are the 
suitable surgical candidates
5. Resection involves a 
standard pancreaticoduodenectomy or a distal 
pancreatectomy, majority of the times, but a 
median or extended pancreatectomy may be carried 
out if indicated depending upon the location of 
secondary deposit with or without resection of the 
inferior vena cava (IVC) when the IVC is involved 
by the metastatic tumor
5, 9. 
Atypical resection such as duodenum preserving 
pancreatic head resection, median pancreatectomy 
and enucleation of the tumor has been adopted on 
the basis of the fact that these lesions are well 
encapsulated. A relatively good prognosis has been 
observed in the absence of spread to lymph nodes 
and in local recurrence
2,4. Bassi et al
4, adopting a 
policy of atypical resection, observed a 29% rate of 
pancreatic recurrence (5 out of 17 cases). 22.3% of 
patients show widespread disease at surgery for 
suspected isolated RCC metastasis to the pancreas 
and 17.1% develop extra-pancreatic recurrence 
after resection
5. 
However, others feel that, since the frequency of 
multiple metastasis is often more than 2 (average 
3.2), the choice of a standard or an atypical 
procedure is then probably less important than a 
careful search for multiple metastasis
2. Pancreatic 
metastases intraoperatively are detected by a 
combination of complete pancreatic mobilisation, 
careful manual palpation and intraoperative 
ultrasonography. Multifocal pancreatic metastasis 
has been reported to be in the range of 20-45%
2- 4. 
Zerbi et al
2 reported an increase in multifocality 
from 17.4% to 34.8% on pathological examination 
of resected specimens. 
Surgical treatment of isolated pancreatic metastasis 
from neoplasms other than renal cell carcinoma 
carries a poor prognosis as they signal the onset of 
disseminated metastatic disease
3. The outcome of 
isolated pancreatic metastasis from renal cell 
carcinoma is clearly superior with a mean 5 year 
survival ranging from 43 to 88% which is even 
better than that of primary adenocarcinoma of 
pancreas
2, 3. 
Tanis et al
5, systematically reviewed more than 400 
patients with pancreatic metastases from RCC. 
Factors associated with favorable prognosis include 
a long disease-free interval, preferably more than 2 
years, after resection of primary tumor, a single, 
asymptomatic, metastatic deposit with central 
necrosis and complete excision of the secondary 
deposit with histologically negative margins in a 
candidate fit to undergo pancreatic surgery. 
Previous surgeries to excise isolated metastasis at 
extra pancreatic sites should not be an exclusion 
criterion
5, 7. 
Some have reported that the tumor grade of 
pancreatic metastasis correlated with the grade of 
the primary renal cell carcinoma. The tumor grade 
was a predictor of survival with a median survival 
of 41 months for grade II and 10 months for grade 
III cancer
1. 
The overall 24 and 60 month survival probabilites 
are reported to be 0.84 and 0.53, respectively, in 
patients who underwent resection
4. Corresponding 
values of survival probability at 24 and 60 months 
in patients treated conservatively were 0.53 and 
0.26, and the difference between the two groups 
was significant (p=0.040)
4. Reddy et al
1 noted that, 
the 5 year survival rate was 80% from the time of 
the pancreatic metastatectomy in seven out of 
eleven studies whereas Tanis et al, noted that the 2 
and 5 year disease free survival rates after resection 
of pancreatic RCC metastases were 76% and 57%
5. 
The overall survival rates were 80.6% and 72.6% 
respectively
5. 
Immunoreactive cytokines used for metastatic renal 
cell carcinoma earlier are now being replaced by 
systemic agents, such as bevacizumab, sunitinib, 
temsirolimus and sorafenib which have shown 
promising results in phase III trials
10. Sorafenib 
prolonged progression free survival in patients with 
advanced renal cell carcinoma
11. However, 
treatment is associated with toxic effects including 
diarrhea, rash, fatigue, head and foot skin reaction 
and occasionally hypertension and cardiac events
11. 
In the presence of extra pancreatic recurrence, 
improved survival rates have been achieved (5 year 
survival rate of 88%) by combination of pancreatic 
resection and use of immunotherapy
2. Also, in 
cases showing an aggressive growth pattern i.e. a Bhalla et al / Solitary pancreatic metastasis from renal cell carcinoma 
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short disease free interval from the primary RCC or 
a short interval between sequentially resected 
metastases, a probable recommendation is to start 
on systemic therapy and restage after a couple of 
months
5, surgery being considered in patients in 
remission or with stable disease. Systemic therapy 
may also be considered in cases of extra pancreatic 
disease at exploration or as a neoadjuvant therapy 
in locally unresectable disease
5. 
 
CONCLUSION 
 
Pancreatic metastasis from renal cell carcinoma, 
although rare, may present years after resection of 
the primary renal cell carcinoma. When possible, 
complete surgical resection offers the best chance 
of cure. Local recurrence or a new site of tumor in 
the pancreas may be treated actively with a total 
pancreatectomy. Previously resected renal cell 
carcinoma metastasis at other sites, should not 
discourage aggressive treatment of an isolated 
pancreatic secondary tumor. Surgical treatment of 
pancreatic metastasis from neoplasms other than 
renal cell carcinoma has a poor prognosis. 
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